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Abstract
Children and adolescents with gender and sex diversity include (1) gender-nonconforming and transgender individuals for whom gender identity or expression are incongruent with birth-assigned sex (heretofore, transgender) and (2) individuals who have differences in sex development (DSD). Although these are largely disparate
groups, there is overlap in the medical expertise necessary to care for individuals with both gender and sex diversity. In addition, both groups face potential infertility or sterility as a result of desired medical and surgical therapies. The Ann & Robert H. Lurie Children’s Hospital of Chicago (Lurie Children’s) gender and sex development
program (GSDP) provides specialized multidisciplinary care for both transgender and DSD patients. In response
to patient concerns that recommended medical treatments have the potential to affect fertility, the Lurie Children’s GSDP team partnered with experts from the Oncofertility Consortium at Northwestern University to expand
fertility preservation options to gender and sex diverse youth. This article summarizes the results of a meeting of
experts across this ﬁeld at the annual Oncofertility Consortium conference with thoughts on next steps toward a
uniﬁed protocol for this patient group.
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Introduction
Oncofertility emerged over the last decade as a ﬁeld that
aims to preserve fertility for cancer patients undergoing treatments, including chemotherapy and radiation, which can lead to infertility.1,2 To expand fertility
preservation to gender and sex diverse individuals, the
Lurie Children’s gender and sex development program
(GSDP) team took the following initial steps: (1) discussed formative experiences with the leaders in the
Oncofertility Consortium, (2) reviewed the limited research available on fertility in transgender and DSD patient populations, and (3) mapped the issues faced in
expanding fertility preservation to individuals with gender and sex diversity. Speciﬁcally, the Lurie Children’s
GSDP team documented risks of infertility, the effects
of medical and surgical intervention, and psychosocial
concerns and ethical considerations in each population.
Although members of both the transgender and DSD
communities face infertility, the reasons for fertility challenges largely differ between the two groups. Transgender
youth possess inherently normal reproductive capability,
but face potential infertility as a result of medical treatments intended to facilitate phenotypic transition to an
afﬁrmed gender. Pubertal suppression treatment, prescribed to youth with gender dysphoria as early as Tanner
stage 2 of puberty, pauses the development of an undesired puberty, including some irreversible secondary sexual characteristics, but also prevents maturation of
primary oocytes and spermatogonia to mature oocytes
and sperm. Gender-afﬁrming hormone treatment with
exogenous estrogen and testosterone in adolescence
may affect fertility, but the threshold at which sex steroid
treatment impairs fertility is unknown.3
In contrast, DSD conditions are often associated
with abnormal gonadal development, progressive gonadal failure over the ﬁrst two decades of life, and/or
abnormal hormone production, all of which can cause
infertility.3 Furthermore, DSD conditions may be associated with elevated risk for germ cell cancer4; thus, traditionally, gonadectomy was recommended for some
DSD conditions, in which infertility was presumed
and risk of germ cell cancer was high.
From these early efforts, the Lurie Children’s GSDP
team synthesized six representative clinical scenarios (Figs. 1 and 2) to promote discussion. Appreciating
the need to gather further expertise, a working group
session about fertility preservation for individuals with
gender and sex diversity was convened at the November
2015 Oncofertility Consortium Meeting in Chicago, Illinois. Attendees included those with expertise in fertility
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preservation and/or clinical treatment of transgender
and DSD patients, with foundational training in the following disciplines: bioethics, reproductive endocrinology, pediatric psychology, pediatric urology, pediatric
and adolescent gynecology, pediatric endocrinology,
and adolescent medicine. Each scenario in Figures
1and 2 was discussed with particular emphasis on technical needs, necessary team members, psychosocial
concerns, ethical concerns, and barriers to care, including the cost of procedures. Proceedings of the session
are summarized.
Fertility Preservation Options
for Postpubertal Youth
Individuals who have completed pubertal development
are reproductively mature. For those with ovarian tissue,
options for fertility preservation include the following:
(1) embryo banking, which requires hormonal stimulation for retrieval and a suitable sperm donor, (2) oocyte
banking, also requiring hormonal stimulation for retrieval, and (3) ovarian tissue cryopreservation, which
requires retransplantation in the future, or in vitro maturation techniques, which are currently experimental.5
While still experimental, there have been at least 60
live births following tissue transplant and either
in vitro fertilization with induction of oocyte maturation
or natural pregnancies.6 For those with testicular tissue,
sperm is obtained for cryopreservation through masturbation or testicular sperm extraction. Testicular tissue
cryopreservation is also possible, but as with ovarian tissue cryopreservation, remains investigational.7
Special considerations for transgender youth
Attendees discussed scenarios 1a–b noting that postpubertal transgender youths face speciﬁc challenges surrounding fertility preservation. First, given that the
threshold at which gender-afﬁrming hormones affect fertility is unknown, optimal timing for fertility preservation is likely before initiation of hormone treatment
and, therefore, pursuing preservation procedures may
delay hormone treatment. It can take several weeks
from the time a patient expresses interest in fertility preservation to actually moving forward with scheduled procedures. In addition, an oocyte harvesting cycle,
speciﬁcally, requires on average an additional 2 weeks
and hormonal stimulation of the ovaries. Transgender
individuals often experience long-standing gender dysphoria and may ﬁnd delaying gender-afﬁrming hormone
treatment, even by a few weeks, distressing. Furthermore, among transmasculine individuals, hormonal
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FIG. 1.
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Transgender fertility preservation scenarios.

stimulation of the ovaries results in increased estrogen,
which patients may ﬁnd unacceptable.
Second, the techniques required for preservation are
invasive and may exacerbate body dysphoria, which is
frequently present among transgender individuals.
Oocyte harvesting requires vaginal penetration for ultrasound monitoring and for oocyte retrieval. The simplest method of sperm retrieval is by masturbation.

Such penetration or stimulation of anatomy incongruent with gender identity may be particularly distressing.
Third, the harvested gametes will not match gender identity. To our knowledge, no qualitative studies exist that
examine whether the type of gametes to be harvested
would impact an individual’s choice to pursue fertility
preservation. There have been documented cases of
biological parenthood in transgender individuals,8
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DSD fertility preservation scenarios. DSD, differences in sex development.

suggesting that congruence between gamete type and
gender identity is not necessary for individuals who
choose to pursue genetic parenthood.
Special considerations for youth with differences
in sex development
Review of scenarios 2 a and b elicited issues speciﬁc to
postpubertal youth with DSD. As noted above, reduced
inherent fertility potential is a strong possibility in
some DSD conditions, thus there is no guarantee of

viable oocytes or sperm. Premature gonadal failure is
common; however, due to variation in timing, the window of opportunity for preservation is unpredictable.
Moreover, youth and parents may be heavily burdened
as they consider the complicated topic of fertility preservation while weighing the risks and beneﬁts of potential gonadectomy to prevent germ cell cancer. Also
speciﬁc to this population, many DSD conditions are
known to be caused by a genetic mutation, with the
possibility of transmission to offspring. As such, it is
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important to discuss risk for intergenerational transmission of DSD and availability of preimplantation genetic screening. As with the transgender population,
gametes may not match gender identity. Anecdotally,
DSD clinical care providers have expressed concern
that patients and families may struggle to conceptualize
the use of gametes incongruent with gender identity,
but studies have not evaluated this question, thus the
implications on an individual’s decision to pursue fertility preservation are unknown. Finally, timing of DSD
diagnosis may inﬂuence an individual’s willingness to
carefully evaluate options for fertility preservation.
Many of these conditions are detected during adolescence, a developmental period that is critical for identity formation9 and during which sensitivity to privacy
and emotional and cognitive functioning is particularly
essential.10 Adolescence also marks a developmental
period during which sexuality and sexual identity are
explored.11 As such, a DSD diagnosis, particularly
one in which an individual’s gonads are incongruent
with gender identity and assigned sex at birth (e.g.,
Complete Androgen Insensitivity Syndrome), may
devastate an adolescent’s sense of personal identity
and self-esteem10 precluding careful consideration of
options for fertility preservation.
Fertility Preservation Options
for Pre- and Peripubertal Youth
Maturation of gametes occurs during puberty, as
shown in Figure 3. For individuals who have reached

FIG. 3.

Tanner Stage 3–4, mature oocytes or sperm may be
present, allowing preservation options similar to postpubertal youth. Individuals who have not yet reached
sexual maturity, however, do not possess mature oocytes or sperm and are, therefore, limited in options
for fertility preservation (see scenarios 1c,d, and 2c).
Ovarian and testicular tissue may be harvested through
biopsy or gonadectomy and cryopreserved. The ﬁrst
live birth following ovarian tissue autotransplantation
from a pubertal, but premenarchal girl, was recently
reported; thus, this may increasingly become an option.12 In vitro follicle growth of ovarian tissue or maturation of sperm, however, remains investigational. As
such, attendees unanimously agreed that such procedures must be performed under a protocol approved
by an institutional review board (IRB) at an institution
with expertise in these techniques. Protocols should be
speciﬁc to the population, either gender or sex diverse
youth. Inclusive language, such as gonad, rather than
ovary or testicle, allows for preservation of either type
of tissue, regardless of gender identity and is inclusive
of individuals with ovotesticular DSD, who possess
both ovarian and testicular tissue.
Special considerations for transgender youth
Considerations speciﬁc to pre- and peripubertal transgender youth with gender dysphoria include decisions
about whether and when to pursue medical treatment
to facilitate physical transition. Current guidelines for
medical treatment of transgender youth with gender

Spermatogenesis and oogenesis.
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dysphoria recommend gonadotropin releasing hormone agonists (GnRHa) to pause pubertal development among early pubertal youth as early as Tanner
Stages 2–3.13 Pubertal suppression may alleviate psychological distress related to ongoing or anticipated pubertal changes, prevent progression of secondary sexual
characteristics incongruent with afﬁrmed gender identity, allow time for further exploration of gender identity, and provide families more time for discussion and
decision-making.14 Adolescents with persistent gender
dysphoria may go on to initiate later in adolescence. An
additional effect of GnRHa, however, is preventing
maturation of germ cells, which could be used for biological fertility potential. Preservation of ovarian or testicular tissue using IRB-approved protocol could be
pursued any time before the use of gender-afﬁrming
hormones. Alternatively, the adolescent could allow
some pubertal development to mature gametes, before
hormone treatment, but there was consensus that this
option would likely be less desirable to the youth and
antithetical to the use of GnRHa for prevention of secondary sexual characteristics. The group agreed that
discussion of the fertility effects of GnRHa therapy
should begin before starting treatment. The gender
care provider most well-known to the individual and
family should initiate and repeat these discussions.
Ideally, these conversations would also take place
with the individual’s mental health provider during
the recommended assessment of readiness for medical
interventions as outlined by WPATH15 and Endocrine
Society clinical practice guidelines.13
Special considerations in youth with differences
in sex development
As for postpubertal individuals with DSD, pre- and
peripubertal youth with DSD may face uncertainty
about inherent fertility potential and potential gonadal
insufﬁciency. The group agreed that these questions
complicate recommendations for the optimal timing
of fertility preservation. Preliminary discussions may
begin shortly after birth, in the case of an infant diagnosed with a DSD. Completing diagnostic testing and
understanding the nature of the DSD condition can
be a lengthy process of adjustment for parents, requiring
patience and continued discussion. Conversation about
fertility must continue in earnest if considering gonadectomy. Risk of progressive gonadal failure in early childhood, in conditions such as XO/XY Turner Syndrome
and Klinefelter Syndrome, may advance the ideal timing
of preservation to a younger age when primary oocytes
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are still present. Again, the group recognized the possibility of transmitting a genetic condition to offspring,
highlighting the need to weigh this risk and consider options for preimplantation genetic screening.
Team Approach
The group recommends a team approach for discussing
and implementing fertility preservation procedures in
gender and sex diverse individuals. Working group attendees offered experience with a range of institutional
practice and team members. This led to an understanding that a proper fertility preservation team at one institution may be different than at another, based on the
experience and availability of providers. For example,
there can be overlap in roles of an endocrinologist and
adolescent medicine specialist in the care of transgender
youth or in surgeons’ roles given varying experience
with fertility preservation. In general, however, participants agreed that the team should include members
with training in disciplines as shown in Table 1.
In addition, the group agreed that including other
stakeholders will be essential in guiding the direction
of this ﬁeld. Members of this working group are part
of the National physicians cooperative (NPC), a national
interdisciplinary group of specialists, which provides fertility preservation clinical services to cancer patients, including basic scientists, allied health professionals, and
physician groups (urology, reproductive endocrinology,
general surgery, obstetrics/gynecology, and hematology/oncology). The NPC was born from needs associated
with cancer patients, but now extends to incorporate
other ﬁelds as fertility threats are identiﬁed. The subset
of the NPC for gender and sex diverse individuals should
seek input from youth affected by these conditions and
their parents, as well as advocate for unique and important perspectives from those outside the medical ﬁeld.
Ethical Concerns
In discussing the options for fertility preservation in
gender and sex diverse youth, the group raised many
ethical concerns. First, as in many dilemmas in the pediatric population, issues arise regarding a patient’s
ability to participate meaningfully in medical decisionmaking (i.e., issues related to assent versus consent).
While fertility decisions ideally are made by an individual in adulthood, postponing decision-making may result in missing an optimal window during which
fertility preservation is most likely to be successful. Second, the fact that parents, as the legal guardian and
proxy for the youth, make decisions for their child
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Table 1. Team Approach to Fertility Preservation
Discipline
Psychology/social work
Endocrinology
Adolescent medicine
Urology
Pediatric surgery
Obstetrics/gynecology
Reproductive endocrinology
Ethics
Financial counseling
Genetic counseling
Fundamental reproductive
science

Role on fertility preservation team
Facilitate discussion of desire for biological fertility. Assess individual’s capacity for medical decision-making, family
dynamics, and transgenerational desire for fertility. Provide support for individuals struggling to cope with
potential infertility.
Assess gonadal function and likelihood of biological fertility potential. Discuss fertility-related implications of
medical transition treatments in transgender youth.
Discuss fertility-related implications of medical transition treatments in transgender youth.
Counsel about sperm preservation. Perform testicular biopsy, TESE. Assess internal anatomy and constitution of
gonadal tissue. Perform gonadal biopsy or gonadectomy.
Assess internal anatomy and constitution of gonadal tissue. Perform gonadal biopsy or gonadectomy.
Assess internal anatomy and constitution of gonadal tissue. Perform gonadal biopsy or gonadectomy.
Counsel about and perform ovarian stimulation and oocyte retrieval.
Evaluate individual’s ability to assent/consent. ‘‘Arbitrate’’ in situations, in which parents and youth may disagree on
decisions for fertility preservation.
Discuss financial implications of procedures and storage, often not included in insurance coverage.
Discuss risks of transmission of condition to offspring and role of preimplantation genetics.
Develop new technologies for measuring fertility loss and restoring endocrine and fertility in high-risk cases.

TESE, testicular sperm extraction.

can raise concerns, especially if there are divergent
views. For example, parents’ wishes may differ from
those of their child or may differ between parents sharing legal decision-making rights. Third, providers may
exert pressure due to their own personal biases regarding issues such as alternative options for parenting,
whether to pursue fertility preservation, and the role
of preimplantation genetic screening. Fourth, there is
great concern about the implications of encouraging
‘‘false hope’’ for fertility potential. As reviewed, fertility
potential in many of these conditions is unknown and
in vitro maturation of cryopreserved prepubertal tissue
is experimental, with no guarantee for successful future
use of preserved immature gametes. Thus, the group
suggested using the term ‘‘cryopotential,’’ rather than
cryopreservation, to denote storage of immature tissue,
where the potential for future use is still under development. Finally, ownership of the biological material
must be established and documented before preservation. Adult individuals specify the fate of the material
in the event of their death: donation to research, to another individual, or that the material be destroyed.
Embryos made with a partner’s gametes belong to the
partner. In the pediatric population, current policies
specify that in the event of death, tissue is either
destroyed or donated for research.
Technical Requirements
Success in fertility preservation is a complicated process, dependent on multidisciplinary expertise and speciﬁc technical abilities. Thus, the group determined
that fertility preservation for gender and sex diverse individuals should be offered at centers that can provide

both clinical and technical expertise, with a designated
team leader. In addition to the team speciﬁed in Table
1, pathology expertise is also important to examine and
process the tissue and an assisted reproductive technology and andrology laboratory to further process the
specimens. A patient navigator is extremely helpful to
guide patients through the process, and research assistants are important for regulatory support in opening
and maintaining protocols, as well as collecting data.
One of the roles that the NPC played in the development of the oncofertility ﬁeld was a series of guidelines
and protocols that could be shared and adapted by
practitioners even as larger specialty societies were developing guidelines. Having team members work together across disciplines catalyzes the work.
Table 2. Cost of FP Techniques: Experience of Lurie
Children’s Hospital Oncofertility Team
Technique
Oocyte cryopreservation
Ovarian tissue cryopreservationa
(consultation, oophorectomy,
and freezing of ovary)
Semen analysis
Freezing semen
TESE
Testicular tissue
Cryopreservationa
(consultation, testicular
biopsy, or orchiectomy)
Infectious disease testing
Shipping to storage facility
Yearly storage

a

Experimental.

Cost

Insurance
coverage

$5000–$10,000
$9000–$20,000

No
Variable

$375
$350
$8000
$5500

Usually
No
Variable
Usually

$240
$215
$275 ($75 discount
based on financial
need)

Yes
No
No
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Table 3. Action Items for the Gender and Sex Diverse Working Group
Immediate action items
Initiate a formal review of the bioethical concerns in each population. Of particular importance is the need to address the ethical concerns
related to the experimental nature of some techniques to preserve fertility potential and the lack of data about fertility potential in these patients.
Invite patient advocates from each community to join the working group and provide their crucial perspective.
Build transgender and DSD fertility information into the current Oncofertility website.
Long-term research needed to advance the ﬁeld
Multicenter extension of ongoing Lurie study to determine the presence and quality of germ cells in gonads of patients with disorders in
sex development.
Study gonads in adult transgender patients undergoing sex reassignment surgery to evaluate the effect of hormone treatment on gonadal
function and fertility.
Qualitative study to determine attitudes toward fertility in patients with complete androgen insensitivity syndrome, with a focus on discordance
between gonadal type and gender identity.
Multicenter trials to preserve gonadal tissue and potential fertility in prepubertal gender and sex diverse individuals.
DSD, differences in sex development.

Barriers to Care
In discussing other potential barriers to care, participants identiﬁed geographic and ﬁnancial concerns.
The scarcity of fertility preservation centers limits
some individuals’ ability to pursue fertility preservation, particularly if travel to a center is too burdensome.
Furthermore, the cost of the preservation process itself
may be prohibitive. Potential fees include those for harvesting of tissue or retrieval of gametes (operating
room, surgery, and anesthesia fees), consultation with
fertility preservation specialists, hormones to stimulate
oocyte production, tissue processing fees, and shipping
of gametes or tissue to a storage facility and long-term
storage. Insurance coverage for such procedures is extremely limited and state speciﬁc, although the Oncofertility Consortium has worked to address this
issue.16 Table 2 provides estimated procedure and storage costs at Lurie Children’s, as well as the likelihood of
insurance coverage. It is important to note that these
cost data are institution speciﬁc and include some negotiated pricing. The notations about insurance coverage reﬂect the experience in oncofertility and may be
found to be different in the gender and sex diverse population. Long-term storage remains the individual’s responsibility and need-based ﬁnancial assistance is
offered by some storage facilities. Limited philanthropic support for storage now exists for oncology patients and is a potential avenue for defraying some costs
for gender and sex diverse individuals.
Summary
The inaugural meeting of the Gender and Sex Diversity
Fertility Working Group set the stage for a new ﬁeld in
fertility preservation. This report synthesizes the current
state of the ﬁeld, gaps in knowledge, and goals to address
moving forward (Table 3). Ultimately, the goal of im-

proved care for these populations will be achieved
through collaborative interdisciplinary work.
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